MedPath

BMS-963272

Generic Name
BMS-963272
Clinical Trials
Related News

A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-963272 in Participants With Nonalcoholic Fatty Liver Disease

Phase 1
Terminated
Conditions
Nonalcoholic Fatty Liver Disease
Interventions
Other: Placebo matching BMS-963272
First Posted Date
2021-02-23
Last Posted Date
2022-06-09
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
9
Registration Number
NCT04766476
Locations
🇺🇸

Arizona Liver Health - Tucson, Tucson, Arizona, United States

🇺🇸

Pinnacle Clinical Research - Austin, Austin, Texas, United States

🇺🇸

Local Institution, San Antonio, Texas, United States

and more 4 locations

A Study to Assess the Drug-drug Interaction of BMS-963272 and Rosuvastatin

Phase 1
Completed
Conditions
Healthy Participants
Interventions
First Posted Date
2019-10-11
Last Posted Date
2020-03-10
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
28
Registration Number
NCT04124003
Locations
🇺🇸

PRA Health Sciences - Salt Lake, Salt Lake City, Utah, United States

A Multiple Dose Study to Assess the Safety and Tolerability of BMS-963272 in Obese But Otherwise Healthy Adults

Phase 1
Completed
Conditions
Obese But Otherwise Healthy Participants
Interventions
Drug: Placebo
First Posted Date
2019-10-04
Last Posted Date
2020-05-15
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
36
Registration Number
NCT04116632
Locations
🇺🇸

PRA Health Sciences - Lenexa, Lenexa, Kansas, United States

Randomized, Placebo-Controlled, Double-Blind, Ascending Single and Multiple Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BMS-963272 in Healthy Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Placebo
First Posted Date
2014-12-30
Last Posted Date
2015-07-22
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
88
Registration Number
NCT02327273
Locations
🇺🇸

Ppd Development, Lp, Austin, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy